Anti-Androgen Receptor (phospho Y363) antibody (ab92563)


  • Product nameAnti-Androgen Receptor (phospho Y363) antibody
    See all Androgen Receptor primary antibodies
  • Description
    Rabbit polyclonal to Androgen Receptor (phospho Y363)
  • Specificityab92563 detects endogenous levels of Androgen Receptor only when phosphorylated at tyrosine 363.
  • Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic phosphopeptide derived from Human Androgen Receptor around the phosphorylation site of tyrosine 363 (DYYPNF).

  • Positive control
    • Extracts from Jurkat cells (treated with UV for 15 mins) IHC-P: Human prostate FFPE tissue sections.



Our Abpromise guarantee covers the use of ab92563 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: 1/10000.
    WB: 1/500 - 1/1000. Predicted molecular weight: 99 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
      Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
    • Tissue specificityIsoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
    • Involvement in diseaseAndrogen insensitivity syndrome
      Spinal and bulbar muscular atrophy X-linked 1
      Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
      Androgen insensitivity, partial
    • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
      Contains 1 nuclear receptor DNA-binding domain.
    • DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
    • Post-translational
      Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
      Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
      Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
    • Cellular localizationNucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
    • Information by UniProt
    • Database links
    • FormThere are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
    • Alternative names
      • AIS antibody
      • ANDR_HUMAN antibody
      • Androgen nuclear receptor variant 2 antibody
      • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
      • Androgen receptor antibody
      • androgen receptor splice variant 4b antibody
      • AR antibody
      • AR8 antibody
      • DHTR antibody
      • Dihydro testosterone receptor antibody
      • Dihydrotestosterone receptor (DHTR) antibody
      • Dihydrotestosterone receptor antibody
      • HUMARA antibody
      • HYSP1 antibody
      • KD antibody
      • Kennedy disease (KD) antibody
      • NR3C4 antibody
      • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
      • Nuclear receptor subfamily 3 group C member 4 antibody
      • SBMA antibody
      • SMAX1 antibody
      • Spinal and bulbar muscular atrophy (SBMA) antibody
      • Spinal and bulbar muscular atrophy antibody
      • Testicular Feminization (TFM) antibody
      • TFM antibody
      see all

    Anti-Androgen Receptor (phospho Y363) antibody images

    • IHC image of Androgen Receptor (phospho Y363) staining in human prostate formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab92563, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

      For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    • All lanes : Anti-Androgen Receptor (phospho Y363) antibody (ab92563) at 1/500 dilution

      Lane 1 : extracts from Jurkat cells, treated with UV (15mins)
      Lane 2 : extracts from Jurkat cells, treated with UV (15mins) with immunising peptide at 10 µg

      Lysates/proteins at 30 µg per lane.

      Predicted band size : 99 kDa

    References for Anti-Androgen Receptor (phospho Y363) antibody (ab92563)

    ab92563 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products. I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has cau...

    Read More